Mode of Administration: Subcutaneous

7 trials

Sponsors

Intas Pharmaceuticals Limited, Intas Pharmaceuticals Ltd, INTAS PHARMACEUTICALS LIMITED, Intas Pharmaceuticals Ltd Biopharma Division, Virchow Biotech Private Limited

Conditions

Health Condition 1: C795- Secondary malignant neoplasm of bone and bone marrowHealth Condition 1: D693- Immune thrombocytopenic purpura

Phase 1

A study to assess Inj. Romiplostim in patients with Low levels of the blood cells that prevent bleeding

RecruitingCTRI/2017/11/010620

Intas Pharmaceuticals LimitedHealth Condition 1: D693- Immune thrombocytopenic purpura

Target: 24Updated: 2021-11-24

A Study of INTG8 in Healthy Men and Postmenopausal Women

Active, not recruitingCTRI/2018/09/015697

INTAS PHARMACEUTICALS LIMITED

Target: 99Updated: 2021-11-24

Phase 3

A study of Denosumab in patients with cancer spread to the bone

Active, not recruitingCTRI/2019/01/017364

Intas Pharmaceuticals Ltd Biopharma DivisionHealth Condition 1: C795- Secondary malignant neoplasm of bone and bone marrow

Target: 150Updated: 2021-11-24

Comparative biosimilar Denosumab versus Xgeva in patients with bone metastasis from solid tumours

RecruitingCTRI/2024/06/068269

Virchow Biotech Private LimitedHealth Condition 1: C795- Secondary malignant neoplasm of bone and bone marrow

Target: 230Updated: 2026-06-01

Unknown Phase

A Study of Injections of Pegfilgrastim in Healthy, Adult Human Subjects.

Active, not recruitingCTRI/2018/02/011700

Intas Pharmaceuticals Ltd

Target: 144Updated: 2021-11-24

A Study of Pegfilgrastim in Healthy, Adult, Human Subjects Under Fed Condition.

Active, not recruitingCTRI/2018/02/011937

Intas Pharmaceuticals Ltd

Target: 200Updated: 2021-11-24

A study of recombinant human follicle stimulating hormone (r-hFSH) of Intas Pharmaceuticals Ltd. with Gonal-F in healthy female subjects

Active, not recruitingCTRI/2018/11/016335

Intas Pharmaceuticals Limited

Target: 56Updated: 2021-11-24